u3-1402
mAbexperimentalADC
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02980341)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 2
- Head and Neck Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Melanoma · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 2
- Stomach Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 2
Mechanism of action
ERBB3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- deruxtecan
Oral
No
Parenteral
No
Topical
No
Also known as
- u3-1402
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06731907 | Phase 2 | Jan 20, 2025 | Daiichi Sankyo, Merck |
| NCT06172478 | Phase 2 | Jan 28, 2024 | Daiichi Sankyo, Merck |
| NCT04965766 | Phase 2 | May 11, 2021 | Daiichi Sankyo, Institut Gustave Roussy |
| NCT04699630 | Phase 2 | May 3, 2021 | Daiichi Sankyo, SCRI Development Innovations |
| NCT04610528 | Early Phase 1 (Phase 1) | Nov 30, 2020 | Daiichi Sankyo, SOLTI Breast Cancer Research Group |
| NCT04479436 | Phase 2 | Sep 14, 2020 | Daiichi Sankyo |
| NCT03260491 | Phase 1 | Oct 30, 2017 | Daiichi Sankyo |
| NCT02980341 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2016 | Daiichi Sankyo |
| NCT06099639 | N/A | — | Daiichi Sankyo |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 9 | 5 | 3 | 2016 |
| Merck | For profit | 2 | 1 | 1 | 2024 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 1 | 1 | 2021 |
| SCRI Development Innovations | For profit | 1 | 1 | 1 | 2021 |
| SOLTI Breast Cancer Research Group | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1